Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients

Article Gastroenterology & Hepatology

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

Markus Cornberg et al.

Summary: According to a recent estimate by the World Health Organization, the SARS-CoV-2 pandemic has affected nearly 100 million people globally, with patients with chronic liver diseases (CLD) at higher risk of infections. Vaccination against various pathogens, including SARS-CoV-2, is important for these patients, although impaired immune responses may affect the efficacy of immunization. The safety, immunogenicity, and efficacy of SARS-CoV-2 vaccines in patients with CLD, cirrhosis, hepatobiliary cancer, and liver transplant recipients still require further study.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Surgery

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Ayelet Grupper et al.

Summary: Only 37.5% of transplant recipients developed a positive immune response to the Pfizer vaccine, with lower antibody levels, and factors associated with null immune response include older age, high-dose corticosteroids use, triple immunosuppression maintenance, and regimen with mycophenolate.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response

Yael Peled et al.

Summary: The study investigated the safety and efficacy of BNT162b2 vaccine in heart transplant recipients, showing a low rate of adverse events and some individuals developing antibody responses. The presence of IgG anti-RBD antibodies was associated with neutralizing SARS-CoV-2 pseudo-virus, but certain immunosuppressive regimens may impact the odds of an antibody response. Further research is needed to determine the optimal observation period for antibody response in immunocompromised individuals.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Liane Rabinowich et al.

Summary: Liver transplant recipients showed significantly lower immunological response to the Pfizer-BioNTech SARS-CoV-2 mRNA-based vaccine, with less than half developing sufficient levels of antibodies and lower average antibody levels compared to healthy controls. Predictors for non-response included older age, renal function and immunosuppressive medications.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Letter Critical Care Medicine